


## Viral dynamics in mild and severe cases of COVID-19

Coronavirus disease 2019 (COVID-19) is a new pandemic disease. We previously reported that the viral load of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) peaks within the first week of disease onset.<sup>1,2</sup> Findings from Feb, 2020, indicated that the clinical spectrum of this disease can be very heterogeneous.<sup>3</sup> Here, we report the viral RNA shedding patterns observed in patients with mild and severe COVID-19.

76 patients admitted to the First Affiliated Hospital of Nanchang University (Nanchang, China) from Jan 21 to Feb 4, 2020, were included in the study. All patients were confirmed to have COVID-19 at the time of admission by RT-PCR. The viral loads of their nasopharyngeal swab samples were estimated with the  $\Delta Ct$  method ( $Ct_{\text{sample}} - Ct_{\text{ref}}$ ). Patients who had any of the following features at the time of, or after, admission were classified as severe cases: (1) respiratory distress ( $\geq 30$  breaths per min); (2) oxygen saturation at rest  $\leq 93\%$ ; (3) ratio of partial pressure of arterial oxygen to fractional concentration of oxygen inspired air  $\leq 300$  mm Hg; or (4) severe disease complications (eg, respiratory failure, requirement of mechanical ventilation, septic shock, or non-respiratory organ failure). 46 (61%) individuals were classified as mild cases and 30 (39%) were classified as severe cases. The basic demographic data and initial clinical symptoms of these patients are shown in the appendix. Parameters did not differ significantly between the groups, except that patients in the severe group were significantly older than those in the mild group, as expected.<sup>4</sup> No patient died from the infection. 23 (77%) of 30 severe cases received intensive care unit (ICU) treatment, whereas none of the mild cases required ICU treatment.

We noted that the  $\Delta Ct$  values



**Figure 2: Viral dynamics in patients with mild and severe COVID-19**

(A)  $\Delta Ct$  values ( $Ct_{\text{sample}} - Ct_{\text{ref}}$ ) from patients with mild and severe COVID-19 at different stages of disease onset. Median, quartile 1, and quartile 3 are shown. (B)  $\Delta Ct$  values of serial samples from patients with mild and severe COVID-19. COVID-19=coronavirus disease 2019. \* $p < 0.005$ .

of severe cases were significantly lower than those of mild cases at the time of admission (appendix). Nasopharyngeal swabs from both the left and right nasal cavities of the same patient were kept in a sample collection tube containing 3 mL of standard viral transport medium. All samples were collected according to WHO guidelines.<sup>5</sup> The mean viral load of severe cases was around 60 times higher than that of mild cases, suggesting that higher viral loads might be associated with severe clinical outcomes. We further stratified these data according to the

day of disease onset at the time of sampling. The  $\Delta Ct$  values of severe cases remained significantly lower for the first 12 days after onset than those of corresponding mild cases (figure A). We also studied serial samples from 21 mild and ten severe cases (figure B). Mild cases were found to have an early viral clearance, with 90% of these patients repeatedly testing negative on RT-PCR by day 10 post-onset. By contrast, all severe cases still tested positive at or beyond day 10 post-onset. Overall, our data indicate that, similar to SARS in 2002–03,<sup>6</sup>



Lancet Infect Dis 2020

Published Online

March 19, 2020

[https://doi.org/10.1016/S1473-3099\(20\)30232-2](https://doi.org/10.1016/S1473-3099(20)30232-2)

See Online for appendix

patients with severe COVID-19 tend to have a high viral load and a long virus-shedding period. This finding suggests that the viral load of SARS-CoV-2 might be a useful marker for assessing disease severity and prognosis.

We declare no competing interests. This work was supported by the Health and Medical Research Fund (Hong Kong) and Emergency Science and Technology Project for COVID-19 of Jiangxi province (202011-2).

**Yang Liu, Li-Meng Yan, Lagen Wan,  
Tian-Xin Xiang, Aiping Le,  
Jia-Ming Liu, Malik Peiris,  
\*Leo L M Poon, \*Wei Zhang  
llmpoon@hku.hk;  
zhangweiliuxin@163.com**

Department of Clinical Microbiology (YL), Department of Infectious Disease (T-XX), Department of Blood Transfusion (AL), Department of Orthopedic Surgery (J-ML), and Department of Respiration (WZ), The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China; and School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China (L-MY, MP, LLMP)

- 1 Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. Viral load of SARS-CoV-2 in clinical samples. *Lancet Infect Dis* 2020; published online Feb 24. [https://doi.org/10.1016/S1473-3099\(20\)30113-4](https://doi.org/10.1016/S1473-3099(20)30113-4).
- 2 Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. *N Engl J Med* 2020; published online Jan 30. DOI:10.1056/NEJMc2001737.
- 3 Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med* 2020; published online Feb 28. DOI:10.1056/NEJMoa2002032.

- 4 Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med* 2020; published online Feb 24. [https://doi.org/10.1016/S2213-2600\(20\)30079-5](https://doi.org/10.1016/S2213-2600(20)30079-5).
- 5 WHO. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases. 2020. <https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117> (accessed March 13, 2020).
- 6 Chu CM, Poon LL, Cheng VC, et al. Initial viral load and the outcomes of SARS. *CMAJ* 2004; **171**: 1349–52.